Antiphospholipid Antibodies

Cognitive and Motor Decline, Neuroimaging and Neuropathology

Zoe Arvanitakis, Ana W. Capuano, Robin L Brey, Debra A. Fleischman, Konstantinos Arfanakis, Aron S. Buchman, Julie A. Schneider, Steven R. Levine, David A. Bennett

Research output: Contribution to journalArticle

Abstract

Background: Few data are available on associations of antiphospholipid (aPL) antibodies with cognitive and motor decline in aging, and cerebrovascular disease on in vivo neuroimaging and postmortem neuropathology. Methods: This longitudinal, clinical-pathologic study (aPL antibodies, brain infarcts, and cognitive and motor decline in aging), was derived from 2 ongoing community-based cohort studies. A panel of 3 aPL antibodies was assayed in serum from 956 older individuals (mean age = 81.1 years; 72% women). Serum was also tested in a subset for markers of inflammation (C-reactive protein [CRP]) and blood-brain barrier breakdown (matrix metalloproteinases, MMPs). Annual clinical evaluations documented cognitive (17 neuropsychological tests) and motor function including parkinsonism. Cerebrovascular disease data were derived from in vivo neuroimaging and postmortem neuropathologic evaluations (699 individuals). We examined associations of aPL with cognitive and motor decline, other serum markers, neuroimaging, and neuropathology. Results: Of 956 individuals, 197 (20.6%) had aPL positivity, defined as positivity on any of the assays, at the time of first measurement. During a mean follow-up of 6.6 years (SD 4), overall aPL positivity was not associated with change in global cognition (estimate = -0.005, SE 0.011; p = 0.622) or parkinsonian signs (estimate = -0.003, SE 0.017; p = 0.860). aPL were not associated with serum CRP or MMPs (both p > 0.268). aPL were not associated with in vivo brain magnetic resonance imaging white matter hyperintensities or infarcts (both p > 0.376). Among those autopsied, aPL were not associated with pathologically confirmed brain infarcts, or cerebral atherosclerosis or arteriolosclerosis (all p≥ 0.447). Conclusions: In older individuals followed longitudinally, aPL do not relate to cognitive or motor decline, inflammation, or cerebrovascular disease on in vivo neuroimaging or postmortem neuropathology.

Original languageEnglish (US)
JournalNeuroepidemiology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Antiphospholipid Antibodies
Cerebrovascular Disorders
Neuroimaging
Matrix Metalloproteinases
C-Reactive Protein
Brain
Arteriolosclerosis
Intracranial Arteriosclerosis
Inflammation
Neuropsychological Tests
Parkinsonian Disorders
Blood-Brain Barrier
Serum
Cognition
Blood Proteins
Cohort Studies
Biomarkers
Magnetic Resonance Imaging
Neuropathology
Cognitive Dysfunction

ASJC Scopus subject areas

  • Epidemiology
  • Clinical Neurology

Cite this

Arvanitakis, Z., Capuano, A. W., Brey, R. L., Fleischman, D. A., Arfanakis, K., Buchman, A. S., ... Bennett, D. A. (2019). Antiphospholipid Antibodies: Cognitive and Motor Decline, Neuroimaging and Neuropathology. Neuroepidemiology. https://doi.org/10.1159/000500157

Antiphospholipid Antibodies : Cognitive and Motor Decline, Neuroimaging and Neuropathology. / Arvanitakis, Zoe; Capuano, Ana W.; Brey, Robin L; Fleischman, Debra A.; Arfanakis, Konstantinos; Buchman, Aron S.; Schneider, Julie A.; Levine, Steven R.; Bennett, David A.

In: Neuroepidemiology, 01.01.2019.

Research output: Contribution to journalArticle

Arvanitakis, Z, Capuano, AW, Brey, RL, Fleischman, DA, Arfanakis, K, Buchman, AS, Schneider, JA, Levine, SR & Bennett, DA 2019, 'Antiphospholipid Antibodies: Cognitive and Motor Decline, Neuroimaging and Neuropathology', Neuroepidemiology. https://doi.org/10.1159/000500157
Arvanitakis, Zoe ; Capuano, Ana W. ; Brey, Robin L ; Fleischman, Debra A. ; Arfanakis, Konstantinos ; Buchman, Aron S. ; Schneider, Julie A. ; Levine, Steven R. ; Bennett, David A. / Antiphospholipid Antibodies : Cognitive and Motor Decline, Neuroimaging and Neuropathology. In: Neuroepidemiology. 2019.
@article{0c1b7c67f0fb4003af78bae583547856,
title = "Antiphospholipid Antibodies: Cognitive and Motor Decline, Neuroimaging and Neuropathology",
abstract = "Background: Few data are available on associations of antiphospholipid (aPL) antibodies with cognitive and motor decline in aging, and cerebrovascular disease on in vivo neuroimaging and postmortem neuropathology. Methods: This longitudinal, clinical-pathologic study (aPL antibodies, brain infarcts, and cognitive and motor decline in aging), was derived from 2 ongoing community-based cohort studies. A panel of 3 aPL antibodies was assayed in serum from 956 older individuals (mean age = 81.1 years; 72{\%} women). Serum was also tested in a subset for markers of inflammation (C-reactive protein [CRP]) and blood-brain barrier breakdown (matrix metalloproteinases, MMPs). Annual clinical evaluations documented cognitive (17 neuropsychological tests) and motor function including parkinsonism. Cerebrovascular disease data were derived from in vivo neuroimaging and postmortem neuropathologic evaluations (699 individuals). We examined associations of aPL with cognitive and motor decline, other serum markers, neuroimaging, and neuropathology. Results: Of 956 individuals, 197 (20.6{\%}) had aPL positivity, defined as positivity on any of the assays, at the time of first measurement. During a mean follow-up of 6.6 years (SD 4), overall aPL positivity was not associated with change in global cognition (estimate = -0.005, SE 0.011; p = 0.622) or parkinsonian signs (estimate = -0.003, SE 0.017; p = 0.860). aPL were not associated with serum CRP or MMPs (both p > 0.268). aPL were not associated with in vivo brain magnetic resonance imaging white matter hyperintensities or infarcts (both p > 0.376). Among those autopsied, aPL were not associated with pathologically confirmed brain infarcts, or cerebral atherosclerosis or arteriolosclerosis (all p≥ 0.447). Conclusions: In older individuals followed longitudinally, aPL do not relate to cognitive or motor decline, inflammation, or cerebrovascular disease on in vivo neuroimaging or postmortem neuropathology.",
author = "Zoe Arvanitakis and Capuano, {Ana W.} and Brey, {Robin L} and Fleischman, {Debra A.} and Konstantinos Arfanakis and Buchman, {Aron S.} and Schneider, {Julie A.} and Levine, {Steven R.} and Bennett, {David A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1159/000500157",
language = "English (US)",
journal = "Neuroepidemiology",
issn = "0251-5350",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Antiphospholipid Antibodies

T2 - Cognitive and Motor Decline, Neuroimaging and Neuropathology

AU - Arvanitakis, Zoe

AU - Capuano, Ana W.

AU - Brey, Robin L

AU - Fleischman, Debra A.

AU - Arfanakis, Konstantinos

AU - Buchman, Aron S.

AU - Schneider, Julie A.

AU - Levine, Steven R.

AU - Bennett, David A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Few data are available on associations of antiphospholipid (aPL) antibodies with cognitive and motor decline in aging, and cerebrovascular disease on in vivo neuroimaging and postmortem neuropathology. Methods: This longitudinal, clinical-pathologic study (aPL antibodies, brain infarcts, and cognitive and motor decline in aging), was derived from 2 ongoing community-based cohort studies. A panel of 3 aPL antibodies was assayed in serum from 956 older individuals (mean age = 81.1 years; 72% women). Serum was also tested in a subset for markers of inflammation (C-reactive protein [CRP]) and blood-brain barrier breakdown (matrix metalloproteinases, MMPs). Annual clinical evaluations documented cognitive (17 neuropsychological tests) and motor function including parkinsonism. Cerebrovascular disease data were derived from in vivo neuroimaging and postmortem neuropathologic evaluations (699 individuals). We examined associations of aPL with cognitive and motor decline, other serum markers, neuroimaging, and neuropathology. Results: Of 956 individuals, 197 (20.6%) had aPL positivity, defined as positivity on any of the assays, at the time of first measurement. During a mean follow-up of 6.6 years (SD 4), overall aPL positivity was not associated with change in global cognition (estimate = -0.005, SE 0.011; p = 0.622) or parkinsonian signs (estimate = -0.003, SE 0.017; p = 0.860). aPL were not associated with serum CRP or MMPs (both p > 0.268). aPL were not associated with in vivo brain magnetic resonance imaging white matter hyperintensities or infarcts (both p > 0.376). Among those autopsied, aPL were not associated with pathologically confirmed brain infarcts, or cerebral atherosclerosis or arteriolosclerosis (all p≥ 0.447). Conclusions: In older individuals followed longitudinally, aPL do not relate to cognitive or motor decline, inflammation, or cerebrovascular disease on in vivo neuroimaging or postmortem neuropathology.

AB - Background: Few data are available on associations of antiphospholipid (aPL) antibodies with cognitive and motor decline in aging, and cerebrovascular disease on in vivo neuroimaging and postmortem neuropathology. Methods: This longitudinal, clinical-pathologic study (aPL antibodies, brain infarcts, and cognitive and motor decline in aging), was derived from 2 ongoing community-based cohort studies. A panel of 3 aPL antibodies was assayed in serum from 956 older individuals (mean age = 81.1 years; 72% women). Serum was also tested in a subset for markers of inflammation (C-reactive protein [CRP]) and blood-brain barrier breakdown (matrix metalloproteinases, MMPs). Annual clinical evaluations documented cognitive (17 neuropsychological tests) and motor function including parkinsonism. Cerebrovascular disease data were derived from in vivo neuroimaging and postmortem neuropathologic evaluations (699 individuals). We examined associations of aPL with cognitive and motor decline, other serum markers, neuroimaging, and neuropathology. Results: Of 956 individuals, 197 (20.6%) had aPL positivity, defined as positivity on any of the assays, at the time of first measurement. During a mean follow-up of 6.6 years (SD 4), overall aPL positivity was not associated with change in global cognition (estimate = -0.005, SE 0.011; p = 0.622) or parkinsonian signs (estimate = -0.003, SE 0.017; p = 0.860). aPL were not associated with serum CRP or MMPs (both p > 0.268). aPL were not associated with in vivo brain magnetic resonance imaging white matter hyperintensities or infarcts (both p > 0.376). Among those autopsied, aPL were not associated with pathologically confirmed brain infarcts, or cerebral atherosclerosis or arteriolosclerosis (all p≥ 0.447). Conclusions: In older individuals followed longitudinally, aPL do not relate to cognitive or motor decline, inflammation, or cerebrovascular disease on in vivo neuroimaging or postmortem neuropathology.

UR - http://www.scopus.com/inward/record.url?scp=85065569280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065569280&partnerID=8YFLogxK

U2 - 10.1159/000500157

DO - 10.1159/000500157

M3 - Article

JO - Neuroepidemiology

JF - Neuroepidemiology

SN - 0251-5350

ER -